Tower Research Capital (TRC)’s Rein Therapeutics RNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding RNTX
Tower Research Capital (TRC)'s RNTX Position: Q3 2026 in Review
Tower Research Capital (TRC) opened a new position in Rein Therapeutics (RNTX) in Q3 2026: 14,740 shares worth $11.9K. The stake represents ﹤0.01% of the portfolio and ranks #4178 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in RNTX as recently as Q1 2026.
Tower Research Capital (TRC) first reported a position in RNTX in Q4 2017 and has held it in 25 quarters since. The position peaked at $13.4K in Q1 2024. 64 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.
- Tower Research Capital (TRC) held 14,740 shares of Rein Therapeutics worth $11.9K as of Q3 2026.
- Rein Therapeutics was a new Tower Research Capital (TRC) position in Q3 2026.
- Rein Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4178 holding.
- Tower Research Capital (TRC) first reported a position in Rein Therapeutics in Q4 2017 and has held it in 25 quarters since.
- Tower Research Capital (TRC)'s Rein Therapeutics position peaked at $13.4K in Q1 2024.
- 64 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.